Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 5,301–5,400 of 10,906
Diepstra, K. L., Bullington, B. W., Premkumar, L., Shook‐Sa, B. E., Jones, C. D., & Pettifor, A. E. (2022) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2022.06.015 · Cited by 10
Reeves, D. B., Bracis, C., Swan, D. A., Burns, E., Moore, M., Dimitrov, D., & Schiffer, J. T. (2021) · Med · doi:10.1016/j.medj.2021.04.012 · Cited by 7
COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019–2022
Khan, A., Zhu, Y., Babcock, H. M., Busse, L. W., Duggal, A., Exline, M. C., Gaglani, M., Gibbs, K. W., Gong, M. N., Ginde, A. A., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126806 · Cited by 9
Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
Mahrokhian, S. H., Tostanoski, L. H., Jacob-Dolan, C., Zahn, R. C., Wegmann, F., McMahan, K., Yu, J., Gebre, M. S., Bondzie, E. A., Wan, H., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00454-4 · Cited by 11
Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar
(2021) · doi:10.1101/2021.12.16.21267902 · Cited by 831
Shapiro, J. R., Park, H.-S., Aytenfisu, T., Caputo, C. A., Lee, J. S., Johnston, T., Li, H., Hauk, P., Jacobsen, H., Li, Y., et al. (2022) · medRxiv · doi:10.1101/2022.03.11.22272269 · Cited by 11
Transmission dynamics are crucial to COVID-19 vaccination policy
Dushoff, J. G., Colijn, C., Earn, D. J. D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105878118 · Cited by 9
Possas, C. D. A., Antunes, A. M. D. S., de Oliveira, A. M., Mendes, C. D. D. S., Ramos, M. P., Schumacher, S. D. O. R., & Homma, A. (2021) · Circular Economy and Sustainability · doi:10.1007/s43615-021-00051-y · Cited by 10
Cosimo, S. D., Lupo-Stanghellini, M., Costantini, M., Mantegazza, R., Ciceri, F., Salvarani, C., Zinzani, P., Mantovani, A., Ciliberto, G., Uccelli, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1002168 · Cited by 8
Levintow, S. N., DiRosa, E. A., Carda-Auten, J., et al. (2022) · American Journal of Public Health · doi:10.2105/ajph.2022.307012 · Cited by 9
Roeder, A. J., Koehler, M. A., Jasbi, P., McKechnie, D., Vanderhoof, J., Edwards, B. A., González‐Moa, M. J., Seit‐Nebi, A. S., Svarovsky, S. A., & Lake, D. F. (2022) · Vaccines · doi:10.3390/vaccines10091459 · Cited by 10
Pueyo, P. P., Ruberte, E. G., Ordás, J. G., Blanco, L. M., Pascual-Figal, D. A., Larrañaga-Moreira, J. M., Gómez-Barrado, J. J., Calle, D. G., Bonet, L. A., Salinas, G. L. A., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02225-0 · Cited by 9
Huang, Q.-L., Lang, Q., Li, Y., Wang, F., Han, X., Luo, L., Duan, X., Cao, X., Wang, Y., Bai, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63084-z · Cited by 16
SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based cohort study
Ray, J. G., & Park, A. L. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059944 · Cited by 9
Wang, Z., Liu, X., Jin, J., Liu, X., Liu, C., Xie, F., Wang, X., An, F., Xiao, B., Cheng, H., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202420308 · Cited by 16
A Comprehensive Dataset of Lipid Nanoparticle Compositions and Properties for Nucleic Acid Delivery
Song, S., Baek, J., & Seo, S. (2025) · Scientific Data · doi:10.1038/s41597-025-06456-w · Cited by 14
Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01614-w · Cited by 33
Walczak, P., & Janowski, M. (2021) · Global Challenges · doi:10.1002/gch2.202100004 · Cited by 10
Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS
Forte, E., Soye, B. J. D., Melani, R. D., Hollas, M. A. R., Kafader, J. O., Sha, B. E., Schneider, J. R., & Kelleher, N. L. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00514 · Cited by 8
The mRNA-Based Innovative Strategy: Progress and Challenges
Zhou, H., Wei, D., Chen, Z., Chen, H., Dong, C., Cai, W., Wang, J., Liu, X., Li, Y., Yang, Y., et al. (2026) · Nano-Micro Letters · doi:10.1007/s40820-025-01906-x · Cited by 24
“…and delivery vector improvement, mRNA vaccines have demonstrated significant clinical efficacy during the COVID-19 pandemic, highlighting hallmark advantages of this platform including expedited manufacturing timelines, superior protective efficacy and eliminated genomic integration risks [20, 27].”
InfluentialSelf-citationAcantholytic Dyskeratosis Post-COVID Vaccination
Yang, K., Prussick, L., Hartman, R., & Mahalingam, M. (2022) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000002150 · Cited by 10
mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19
Kackos, C. M., Surman, S. L., Jones, B. G., Sealy, R. E., Jeevan, T., Davitt, C. J. H., Pustylnikov, S., Darling, T. L., Boon, A. C. M., Hurwitz, J. L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04240-22 · Cited by 9
Molecular basis of Ad5-nCoV vaccine-induced immunogenicity
Dong, D., Song, Y., Wu, S., Wang, B., Peng, C., Zhang, W., Kong, W., Zhang, Z., Song, J., Hou, L., et al. (2025) · Structure · doi:10.1016/j.str.2025.02.009 · Cited by 8
Safety of measles, rubella and mumps vaccines in adults: a prospective cohort study
Neuberger, A., Eyal, N., Biber, A., Avni, C., Adi, B., Drorit, A., Petersiel, N., Hajar, D., Rakedzon, S., & Schwartz, E. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab071 · Cited by 9
Effectiveness of a nation-wide COVID-19 vaccination program in MexicoPreprint
Bello-Chavolla, O. Y., Antonio-Villa, N., Valdés-Ferrer, S., Fermín-Martínez, C., Fernández-Chirino, L., Ramírez-García, D., Mancilla-Galindo, J., Kammar-García, A., Ávila-Funes, J., Zúñiga-Gil, C., et al. (2022) · medRxiv · doi:10.1101/2022.04.04.22273330 · Cited by 18
Risk management and communication plans from SARS to COVID‐19 and beyond
Recchia, V., Aloisi, A., & Zizza, A. (2022) · The International Journal of Health Planning and Management · doi:10.1002/hpm.3545 · Cited by 10
Ghandili, S., Schönlein, M., Wiessner, C., Becher, H., Lütgehetmann, M., Brehm, T. T., Wiesch, J. S. Z., Bokemeyer, C., Sinn, M., Weisel, K. C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235499 · Cited by 9
Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward
Sobia, P., & Archary, D. (2021) · Vaccines · doi:10.3390/vaccines9091001 · Cited by 11
Hibino, M., Watanabe, S., Kamada, R., Tobe, S., Maeda, K., Horiuchi, S., & Kondo, T. (2021) · Internal Medicine · doi:10.2169/internalmedicine.8704-21 · Cited by 9
Terpos, E., Liontos, M., Fiste, O., Zagouri, F., Briasoulis, Α., Sklirou, A. D., Markellos, C., Skafida, E., Papatheodoridi, A. M., Andrikopoulou, Α., et al. (2022) · Cancers · doi:10.3390/cancers14112796 · Cited by 9
Salsone, M., Signorelli, C., Oldani, A., Patone, M., Alberti, V. F., Castronovo, V., Mazzitelli, S., Minerva, M., & Ferini‐Strambi, L. (2023) · Vaccines · doi:10.3390/vaccines11101621 · Cited by 11
Gene therapy for cardiac arrhythmias
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01168-5 · Cited by 12
“Lipid nanoparticles have gained popularity for facilitating non-viral delivery of several FDA-approved RNA therapeutics, including the mRNA-based corona-virus disease 2019 vaccines 82 and patisiran, an RNAi therapeutic used to treat hereditary transthyretin-mediated amyloidosis 40 .”
Aguas, R. J., Bharath, A., White, L. J., Gao, B., Pollard, A. J., Voysey, M., & Shretta, R. (2021) · Nature Communications · doi:10.1038/s41467-021-26449-8 · Cited by 9
Chojecka, D., Pytlos, J., Zawadka, M., Andruszkiewicz, P., Szarpak, Ł., Dzieciątkowski, T., Jaguszewski, M. J., Filipiak, K. J., & Gąsecka, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235667 · Cited by 9
Ibrahim, D. S., Kis, Z., Tak, K., Papathanasiou, M. M., Kontoravdi, C., Chachuat, B., & Shah, N. (2021) · Vaccines · doi:10.3390/vaccines9121460 · Cited by 9
Generalidades, aspectos clínicos y de prevención sobre COVID-19: México y Latinoamérica
Fernández, J. A. M., & Wong‐Chew, R. M. (2021) · Universitas Médica · doi:10.11144/javeriana.umed62-3.gacp · Cited by 25
Fabiani, M., Mateo‐Urdiales, A., Sacco, C., Fotakis, E. A., Battilomo, S., Petrone, D., Manso, M. D., Bella, A., Riccardo, F., Stefanelli, P., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.074 · Cited by 10
COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies
Harris, C. E., Vijenthira, A., Ong, S. Y., Baden, L. R., Hicks, L. K., & Baird, J. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390778 · Cited by 11
Self-citationQin, K., Honjo, K., Sherrill-Mix, S. A., Liu, W., Stoltz, R., Oman, A. K., Hall, L., Li, R., Sterrett, S., Frederick, E. R., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004157 · Cited by 12
A review of neuro-ophthalmic sequelae following COVID-19 infection and vaccination
Shi, J., & Danesh-Meyer, H. V. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1345683 · Cited by 15
Pinnawala, N., Thrastardottir, T. O., & Constantinou, C. (2021) · Current Nutrition Reports · doi:10.1007/s13668-021-00356-2 · Cited by 10
Autoimmune diseases and vaccines against COVID-19. Decision making in uncertain scenarios
Cairoli, E., & Espinosa, G. (2021) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.05.003 · Cited by 16
Padhiar, N. H., Liu, J., Wang, X., Wang, X., Bodnar, B. H., Khan, S., Wang, P., Khan, A. I., Luo, J. J., Hu, W., et al. (2022) · Vaccines · doi:10.3390/vaccines10060858 · Cited by 10
Liatsos, G. D. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i16.2397 · Cited by 11
Lapi, F., Marconi, E., Rossi, A., & Cricelli, C. A. (2024) · Family Practice · doi:10.1093/fampra/cmae009 · Cited by 11
Sahn, B. A., Lu, Y., Hui‐Yuen, J. S., Fishbein, J. S., Gottlieb, B. S., Eberhard, B. A., & Walters, H. M. (2022) · Acta Paediatrica · doi:10.1111/apa.16652 · Cited by 9
Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety
Luo, C., Du, J., Cuker, A. C., Lautenbach, E., Asch, D. A., Poland, G. A., Tao, C., & Chen, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-13809-7 · Cited by 12
Jaishwal, P., Jha, K., & Singh, S. P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134012 · Cited by 12
Magalis, B. R., Mavian, C. N., Tagliamonte, M. S., Rich, S. N., Cash, M. N., Riva, A., Loeb, J. C., Norris, M. H., Amador, D. M., Zhang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27726 · Cited by 10
Chimeric Antigen Cytotoxic Receptors for In Vivo Engineering of Tumor-Targeting NK Cells
Diwanji, N., Getts, D. R., & Wang, Y. (2024) · ImmunoHorizons · doi:10.4049/immunohorizons.2300099 · Cited by 11
Sokhangouy, S. K., Behzadi, M., Rezaei, S., Farjami, M., Haghshenas, M., Sefidbakht, Y., & Mozaffari‐Jovin, S. (2025) · Biotechnology Journal · doi:10.1002/biot.202400596 · Cited by 12
Quiroga, B., Soler, M. J., Ortíz, A., & de Sequera, P. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.04.005 · Cited by 10
Datar, R. S., Fette, L. M., Hinkelman, A. N., Hammershaimb, E. A., Friedman-Klabanoff, D. J., Mongraw‐Chaffin, M., Weintraub, W., Ahmed, N., Gibbs, M. A., Runyon, M. S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.057 · Cited by 10
Sousa, M. J., Caramujo, C., Júlio, N., Magalhães, J. C., Basto, R., Fraga, T., Gomes, I. F., Monteiro, A. R., Pazos, I., & Sousa, G. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-06886-x · Cited by 10
ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIVPreprint
Madhi, S. A., Koen, A. L., Fairlie, L., Cutland, C., Baillie, V. L., Padayachee, S. D., Dheda, K. U. J., Barnabas, S. L., Bhorat, Q. E., Briner, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-322470/v1 · Cited by 10
Ruggeri, E. M., Nelli, F., Fabbri, A., Onorato, A., Giannarelli, D., Berrìos, J. R. G., Virtuoso, A., Marrucci, E., Mazzotta, M., Schirripa, M., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100350 · Cited by 10
Bazin, R., Rochette, S., Perreault, J., Fournier, M., Grégoire, Y., Boivin, A., Lewin, A., Germain, M., & Renaud, C. (2023) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2023.2195938 · Cited by 12
Butt, A. A., Peng, Y., Shaikh, O. S., Talisa, V. B., Omer, S. B., & Mayr, F. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad393 · Cited by 9
An Appraisal of the Current Scenario in Vaccine Research for COVID-19
Chong, W. C., Chellappan, D. K., Shukla, S. D., Peterson, G. M., Patel, R. P., Jha, N. K., Eri, R. D., Dua, K., Tambuwala, M. M., & Shastri, M. D. (2021) · Viruses · doi:10.3390/v13071397 · Cited by 9
Amano, M., Otsu, S., Maeda, K., Uemura, Y., Shimizu, Y., Omata, K., Matsuoka, M., Shimada, S., & Mitsuya, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-17071-9 · Cited by 10
Whitaker, M. D., Elliott, J., Gerard-Ursin, I. C. G., Cooke, G., Donnelly, C. A., Ward, H., Elliott, P., & Chadeau‐Hyam, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)01912-9 · Cited by 16
Tian, Z., Wang, X., Chatterjee, S., Miller, W., Guerrero, E. D., Sung, Y., Benitez, A. P., Dilliard, S. A., Bian, X., Vaidya, A., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01615-9 · Cited by 14
Trümpelmann, S., Schulte‐Mecklenbeck, A., Steinberg, O. V., Wirth, T., Fobker, M., Lohmann, L., Lünemann, J. D., Wiendl, H., Groß, C. C., & Klotz, L. (2022) · Clinical and Translational Science · doi:10.1111/cts.13256 · Cited by 7
Saini, A., Li, S., Wang, Z., Plebanski, M., & Ju, Y. (2026) · ACS Nano · doi:10.1021/acsnano.6c00334 · Cited by 17
Why do people consent to receiving SARS-CoV-2 vaccinations? A representative survey in Germany
Walach, H., Ofner, M., Ruof, V., Herbig, M., & Klement, R. J. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060555 · Cited by 14
Velardo, F., Watson, V., Arwidson, P., Alla, F., Luchini, S., Schwarzinger, M., & CoVaMax Study Group (2021) · Vaccines · doi:10.3390/vaccines9111364 · Cited by 8
Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2Preprint
Dangi, T., Sanchez, S., Park, M.-C., Class, J., Richner, M., Richner, J. M., & Penaloza‐MacMaster, P. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.09.483635 · Cited by 8
Hao, M., Edmonds, C. E., Nachiappan, A. C., et al. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.27118 · Cited by 9
TLR7-Adjuvanted Ionizable Lipid Nanoparticles for mRNA Vaccine Delivery
Misra, B., Hughes, K. A., Pentz, W. H., Surface, M., Geldenhuys, W. J., & Bobbala, S. K. R. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01073-2 · Cited by 12
de la Torre, J. C. G., Cáceres-DelAguila, J. A., Muro-Rojo, C., Cruz-Escurra, N. D. L., Corzo, C. A. C., Hueda-Zavaleta, M., Siles, D. A., & Benites-Zapata, V. A. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7050066 · Cited by 11
Tomioka, K., Uno, K., & Yamada, M. (2023) · Environmental Health and Preventive Medicine · doi:10.1265/ehpm.22-00199 · Cited by 9
Drainas, A. P., McIlwain, D. R., Dallas, A. E., Chu, T. P., Delgado‐González, A., Baron, M., Angulo‐Ibáñez, M., Trejo, A., Bai, Y., Hickey, J. W., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01349-0 · Cited by 11
Recent progress in macromolecules: From current therapeutic strategies to theranostic applications
Kumar, S., Garg, N. K., Jain, A., Pandey, P., Khopade, A. J., & Sawant, K. K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105664 · Cited by 11
Stupica, D., Collinet‐Adler, S., Kejžar, N., Jagodic, Z., Poljak, M., & Klevišar, M. N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051191 · Cited by 12
Cauchi, M., Ball, H. A., Ben‐Shlomo, Y., & Robertson, N. P. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10747-8 · Cited by 11
Exploring computational approaches to design mRNA Vaccine against vaccinia and Mpox viruses
Oladipo, E. K., Oyelakin, O. D., Aiyelabegan, A. O., Olajide, E. O., Olatayo, V. O., Owolabi, K. P., Shittu, Y. B., Olugbodi, R. O., Ajala, H. A., Rukayat, R. A., et al. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1360 · Cited by 12
Zhang, Q., & Friedman, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010963 · Cited by 14
Frequent Onsets of Cellulitis in Lower Limbs with Lymphedema Following COVID-19 mRNA Vaccination
Okazaki, T., Matashiro, M., Kodama, G., et al. (2022) · Vaccines · doi:10.3390/vaccines10040517 · Cited by 9
Donhauser, L. V., de Oliveira, J. V., Schick, C., Manlik, W., Stýblová, S., Lutzenberger, S., Aigner, M., Philipp, P., Robert, S., Gandorfer, B., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007387 · Cited by 9
Tan, R., Huang, G., Wei, C., He, Z., Zhao, T., Shi, Y., Liu, Z., & Chen, Y. (2024) · Journal of Polymer Science · doi:10.1002/pol.20240154 · Cited by 10
Badshah, M. B., Shriver, J., Rynders, B., Sjovold, A., Shaukat, M. H. S., & Rajpurohit, N. (2021) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2021.09.007 · Cited by 9
Therapeutic development targeting host heparan sulfate proteoglycan in SARS-CoV-2 infection
Zhang, Q., Pavlinov, I., Ye, Y., & Zheng, W. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1364657 · Cited by 11
Angleró-Rodríguez, Y., Lempp, F. A., Subramanian, M. P., McIninch, J., Schlegel, M. K., Bohan, D., Wong, E. Y. M., Brown, C. R., Foster, D. J., Castoreno, A. B., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1195 · Cited by 11
The BNT162b2 mRNA vaccine demonstrates reduced age-associated TH1 support in vitro and in vivo
Brook, B., Fatou, B., Checkervarty, A., Barman, S., Sweitzer, C., Bosco, A.-N., Sherman, A., Baden, L., Morrocchi, E., Sánchez‐Schmitz, G., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111055 · Cited by 16
Self-citationChoi, M. J., Heo, J. Y., Seo, Y. B., Yoon, Y. K., Sohn, J. W., Noh, J. Y., Cheong, H. J., Kim, W. J., Choi, J., Kim, H. J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035441 · Cited by 11
Sakamoto, A., Yoshimura, M., Itoh, R., Ozuru, R., Ishii, K., Sechi, Y., Nabeshima, S., & Hiromatsu, K. (2022) · Vaccines · doi:10.3390/vaccines10060830 · Cited by 9
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients
Stanghellini, M. T. L., Cosimo, S. D., Costantini, M., Monti, S. M., Mantegazza, R., Mantovani, A., Salvarani, C., Zinzani, P. L., Inglese, M., Ciceri, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.855723 · Cited by 9
Mancuso, K., Zamagni, E., Solli, V., Gabrielli, L., Leone, M., Pantani, L., Rocchi, S., Rizzello, I., Tacchetti, P., Ghibellini, S., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1208741 · Cited by 11
Chen, C., Li, J., Zhou, Y., Zhang, Y., Huang, R., Zhang, Y., Li, J., & Chen, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1624290 · Cited by 14
Soldatov, A. A., Kryuchkov, N. A., Витальевич, Г. Д., Авдеева, Ж. И., Свитич, О. А., & Soshnikov, S. S. (2025) · Vaccines · doi:10.3390/vaccines13080789 · Cited by 13
Temtanakitpaisan, Y., Saengnipanthkul, S., Sarakosol, N., Maskasame, S., Mongkon, S., Buranrat, B., Thammawat, S., Patamatamkul, S., & Nernsai, P. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100242 · Cited by 9
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.